Clinical toxicologic and pharmacologic studies of gallium nitrate
- 1 November 1979
- Vol. 44 (5) , 1722-1727
- https://doi.org/10.1002/1097-0142(197911)44:5<1722::aid-cncr2820440528>3.0.co;2-c
Abstract
Gallium nitrate, administered intravenously to patients with advanced cancer, produced renal functional abnormalities consistently at a dose of 750 mg/m2. The toxicity at that dose could be modified by fluid loading and osmotic diuresis. Pharmacokinetic studies revealed a biphasic half-life, (T 1/2α = 87 minutes and T 1/2β = 24.5 hours). Osmotic diuresis reduced the urinary concentration of gallium but did not affect serum levels or clearance.This publication has 9 references indexed in Scilit:
- Gallium nitrate (NSC-15200) induced toxicity in the rat.A pharmacologic, histopathologic and microanalytical investigationCancer, 1979
- Flameless atomic absorption spectrometry determination of gallium in biological materialsClinica Chimica Acta; International Journal of Clinical Chemistry, 1978
- The renal pathology in clinical trials of Cis-platinum (II) diamminedichlorideCancer, 1977
- High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresisCancer, 1977
- Abnormal Pulmonary Gallium Accumulation inP. CariniiPneumoniaRadiology, 1976
- LOCALISATION OF GALLIUM-67 IN MALIGNANT NEOPLASMSThe Lancet, 1970
- Scanning Malignant Neoplasms With Gallium 67JAMA, 1970
- STUDIES OF THE TOXIC ACTION OF GALLIUM1949